BR112023024170A2 - Composições farmacêuticas compreendendo um modulador do receptor da rianodina e usos das mesmas - Google Patents
Composições farmacêuticas compreendendo um modulador do receptor da rianodina e usos das mesmasInfo
- Publication number
- BR112023024170A2 BR112023024170A2 BR112023024170A BR112023024170A BR112023024170A2 BR 112023024170 A2 BR112023024170 A2 BR 112023024170A2 BR 112023024170 A BR112023024170 A BR 112023024170A BR 112023024170 A BR112023024170 A BR 112023024170A BR 112023024170 A2 BR112023024170 A2 BR 112023024170A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- receptor modulator
- disease
- present disclosure
- disclosure provides
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191142P | 2021-05-20 | 2021-05-20 | |
| PCT/US2022/030111 WO2022246114A2 (en) | 2021-05-20 | 2022-05-19 | Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024170A2 true BR112023024170A2 (pt) | 2024-02-06 |
Family
ID=84141833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024170A BR112023024170A2 (pt) | 2021-05-20 | 2022-05-19 | Composições farmacêuticas compreendendo um modulador do receptor da rianodina e usos das mesmas |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11717526B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4340861A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024519917A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240040681A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117750966A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022279235A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023024170A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3176718A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL308481A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023013744A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022246114A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022150603A1 (en) * | 2021-01-08 | 2022-07-14 | Armgo Pharma, Inc. | Crystalline forms of a ryanodine receptor modulator and uses thereof |
| EP4433062A4 (en) * | 2021-11-16 | 2025-10-22 | Rycarma Therapeutics Inc | THERAPEUTIC COMPOUNDS |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5920219A (ja) * | 1982-07-26 | 1984-02-01 | Shin Etsu Chem Co Ltd | 腸溶性コ−テイング製剤の製造方法 |
| US4775536A (en) * | 1986-02-24 | 1988-10-04 | Bristol-Myers Company | Enteric coated tablet and process for making |
| US8022058B2 (en) | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| JP4414237B2 (ja) | 2002-03-20 | 2010-02-10 | テバ ファーマシューティカル インダストリーズ リミティド | ケチアピンヘミフマレートの結晶形 |
| US8710045B2 (en) | 2004-01-22 | 2014-04-29 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the ryanodine receptors |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20100297226A1 (en) * | 2006-06-01 | 2010-11-25 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
| WO2008060332A2 (en) | 2006-06-02 | 2008-05-22 | The Trustees Of Columbia University In The City Of New York | Methods for treating or reducing muscle fatigue |
| WO2008021439A2 (en) | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of cardiac hypertrophy |
| WO2008021432A2 (en) | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treatment of conditions affecting the nervous system |
| WO2008144483A2 (en) | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| EA028108B1 (ru) | 2008-03-03 | 2017-10-31 | Армго Фарма, Инк. | Способ получения бензотиазепинов из гамма-аминоалкилбензолов |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
| EP2708535A1 (en) * | 2012-05-11 | 2014-03-19 | Les Laboratoires Servier | Agents for treating disorders involving modulation of ryanodine receptors |
| WO2015106268A1 (en) * | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| WO2016109596A1 (en) | 2014-12-30 | 2016-07-07 | Myotherix, Inc. | Novel calcium modulators |
| JP6954927B2 (ja) * | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
-
2022
- 2022-05-19 JP JP2023571950A patent/JP2024519917A/ja active Pending
- 2022-05-19 EP EP22805512.5A patent/EP4340861A4/en active Pending
- 2022-05-19 AU AU2022279235A patent/AU2022279235A1/en active Pending
- 2022-05-19 US US17/748,886 patent/US11717526B2/en active Active
- 2022-05-19 CA CA3176718A patent/CA3176718A1/en active Pending
- 2022-05-19 WO PCT/US2022/030111 patent/WO2022246114A2/en not_active Ceased
- 2022-05-19 IL IL308481A patent/IL308481A/en unknown
- 2022-05-19 BR BR112023024170A patent/BR112023024170A2/pt unknown
- 2022-05-19 MX MX2023013744A patent/MX2023013744A/es unknown
- 2022-05-19 CN CN202280050798.3A patent/CN117750966A/zh active Pending
- 2022-05-19 KR KR1020237044065A patent/KR20240040681A/ko active Pending
-
2023
- 2023-07-13 US US18/221,784 patent/US12059426B2/en active Active
- 2023-07-25 US US18/225,849 patent/US12161650B2/en active Active
-
2024
- 2024-10-31 US US18/933,539 patent/US20250302847A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11717526B2 (en) | 2023-08-08 |
| EP4340861A2 (en) | 2024-03-27 |
| CA3176718A1 (en) | 2022-11-20 |
| EP4340861A4 (en) | 2025-05-28 |
| WO2022246114A3 (en) | 2022-12-15 |
| CN117750966A (zh) | 2024-03-22 |
| US20230364107A1 (en) | 2023-11-16 |
| WO2022246114A2 (en) | 2022-11-24 |
| JP2024519917A (ja) | 2024-05-21 |
| US20230372358A1 (en) | 2023-11-23 |
| KR20240040681A (ko) | 2024-03-28 |
| US12161650B2 (en) | 2024-12-10 |
| MX2023013744A (es) | 2023-12-04 |
| US12059426B2 (en) | 2024-08-13 |
| IL308481A (en) | 2024-01-01 |
| US20220387442A1 (en) | 2022-12-08 |
| AU2022279235A1 (en) | 2023-12-07 |
| US20250302847A1 (en) | 2025-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miyamoto et al. | Antipsychotic drugs | |
| Mallikaarjun et al. | Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study | |
| Abu-Abed et al. | Differential expression of the retinoic acid-metabolizing enzymes CYP26A1 and CYP26B1 during murine organogenesis | |
| Lahti et al. | Functional effects of antipsychotic drugs: comparing clozapine with haloperidol | |
| Muench et al. | Adverse effects of antipsychotic medications | |
| Peuskens et al. | Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia | |
| Durgam et al. | An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression | |
| MX2023013744A (es) | Composiciones farmaceuticas que comprenden un modulador del receptor de rianodina y sus usos. | |
| Benedetti et al. | Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode | |
| von Rüden et al. | Surgical treatment of ipsilateral multi-level femoral fractures | |
| Meltzer | Pharmacotherapy of cognition in schizophrenia | |
| Sereda et al. | Improvement in dermatomyositis rash associated with the use of antiestrogen medication | |
| Ahmed et al. | Successful Isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome | |
| Cummings et al. | Geroscience and Alzheimer’s disease drug development | |
| Skwara et al. | Changes of gait patterns and muscle activity after intraarticular treatment of patients with osteoarthritis of the knee: a prospective, randomised, doubleblind study | |
| JP2009527520A (ja) | 神経芽腫を処置するためのラパマイシン誘導体 | |
| Xu et al. | Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients | |
| RU2007140986A (ru) | Профилактический или терапевтический агент против депрессии или тревожного расстройства | |
| Woroń et al. | Drug-induced diseases in otolaryngology–causes, clinical signs, treatment | |
| Maged | Antipsychotic and anticholinergic drugs | |
| Kennedy et al. | OP0061 Treatment of knee osteoarthritis with sm04690 improved womac a1 ‘pain on walking’–results from a 52 week, randomised, double-blind, placebo-controlled, phase 2 study of a novel, intra-articular, Wnt pathway inhibitor | |
| Keedy et al. | Disease and drug effects on internally-generated and externally-elicited responses in first episode schizophrenia and psychotic bipolar disorder | |
| Kasper | How much do novel antipsychotics benefit the patients? | |
| TW567068B (en) | Medicinal compositions for treating lower uropathy | |
| Numata et al. | Treatment of catatonia with olanzapine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: ARMGO PHARMA, INC. (US) Free format text: A FIM DE ATENDER A ALTERACAO DE NOME E DE SEDE REQUERIDAS ATRAVES DA PETICAO NO 870250038522, DE 12/05/2025, E NECESSARIO APRESENTAR UMA PETICAO PARA A SEGUNDA SOLICITACAO FEITA, UMA VEZ QUE DESDE A PORTARIA 20/2024 NAO E MAIS PERMITIDO SOLICITAR MAIS DE UM SERVICO POR PETICAO. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
| B25D | Requested change of name of applicant approved |
Owner name: RYCARMA THERAPEUTICS, INC. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: RYCARMA THERAPEUTICS, INC. (US) |